ArticleNeurology2016
CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.
Article in Neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 51 citations in OpenAlex.
- Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience.Journal of central nervous system disease · 2022Review
- Immunoprofiling of early, untreated rheumatoid arthritis using mass cytometry reveals an activated basophil subset inversely linked to ACPA status.Arthritis research & therapy · 2021Article
- New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab.Frontiers in neurology · 2020Article
- Risks and risk management in modern multiple sclerosis immunotherapeutic treatment.Therapeutic advances in neurological disorders · 2019Review
- Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review.Blood advances · 2017Article
- Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.Therapeutic advances in neurological disorders · 2017Review
- Progressive multi-focal leucoencephalopathy - driven from rarity to clinical mainstream by iatrogenic immunodeficiency.Clinical and experimental immunology · 2017Review
- The use of natalizumab for multiple sclerosis.Neuropsychiatric disease and treatment · 2017Review
- Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- [Progressive multifocal leukoencephalopathy].Der Nervenarzt · 2016Review
- Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals.Current infectious disease reports · 2016Review
- Review
- Correction: CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.Neurology · 2016Article
- Article
- The effect of disease modifying therapies on CD62L expression in multiple sclerosis.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess if the percentage of CD3(+)CD4(+)CD62L(+) cells in cryopreserved peripheral blood mononuclear cells (PBMCs) (here termed %CD62L) can predict risk of developing progressive multifocal leukoencephalopathy (PML) and better inform the physician for benefit-risk assessment of natalizumab treatment decisions in a global setting.
methodsCryopreserved PBMCs from 21 natalizumab-treated patients who developed PML and 104 matched natalizumab-treated patients with multiple sclerosis (MS) without PML collected as a part of Biogen clinical trials were retrospectively examined for CD3, CD4, CCR7, CD45RA, and CD62L by flow cytometry.
resultsIn this cohort, %CD62L in natalizumab-treated patients did not predict PML risk. Natalizumab-treated patients with MS without PML showed highly variable %CD62L upon serial sampling. In the STRATA study, the distribution of %CD62L in samples collected more than 6 months before a PML diagnosis, at diagnosis, and in natalizumab-treated patients without PML overlapped. No statistical threshold for risk could be determined. In addition, we demonstrated that lymphocyte viability strongly affects %CD62L, supporting previous reports that %CD62L is inherently unstable following cryopreservation and is sensitive to sample collection.
conclusionData from this well-controlled cohort of natalizumab-treated patients indicate that %CD62L is not a biomarker of PML risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.